Bill Liao is a Chinese-Australian-Irish entrepreneur, investor, former diplomat, business mentor, author, passionate leader and speaker, with a distinguished record in business development and community activism. Co-founder of the CoderDojo movement and of Weforest, his career in tech and business encompasses two unicorn companies and launching the world’s first bio-tech accelerator. He is a general partner of SOSV, a venture capital fund of over $1B, and founder of the SOSV Momentum Pre-accelerator program. Bill’s current focus is Quantum Software.

Noor is a serial biotech entrepreneur who is passionate about revolutionizing drug discovery with AI. She combines academic excellence from her Assistant Professorship in AI with deep industrial experience to advance technological innovations. Her research has been recognized with several awards, including MIT innovator under 35 and BBC 100 women. She has served as an AI consultant and member of the advisory board for several organizations.

Danuta is a deep tech entrepreneur and CEO & Co-Founder of Nucleome Therapeutics, with more than 16 years of experience working in the field, Danuta has deep expertise in gene regulation, transcription, epigenetics, 3D genome analysis and bioinformatics. In acknowledgement of her achievements at Nucleome, Danuta was recently recognised as an outstanding leader in the biotech sector by leading scientific journal Nature Biotechnology. She currently sits on the BIA’s Genomics Advisory Committee, holds an Honorary position at the University of Oxford, has a PhD in Systems Biology and a BSc in Biotechnology. Prior to Nucleome she founded Innovation Forum Oxford, for which she was recognised as one of the top Movers and Shakers in BioBusiness in 2018.

Mark Duman MRPharmS is a rare blend of clinician, management consultant and patient advocate. He works with organisations to help them realise the full benefit of their services and products, especially through the often untapped potential of patients and the public. His first foray into digital health was installing the pharmacy component of a Cerner electronic health record system at Health Care International, Scotland in 1994. In Lewisham NHS Hospital he developed the award-winning PharmAssist system harnessing multimedia t to help ethnic minorities with their medicines-taking. At The King’s Fund, Mark promoted shared clinical decision making, founded the Ask About Medicines campaign & authored ‘Producing Patient Information’. Within the BBC, he developed a range of behaviour change interventions to improve people’s health and lifestyle. Following roles in publishing and telecoms, Mark moved into consulting with clients including Cancer Research UK, Care Quality Commission, Pfizer, NHS England and Microsoft. In addition to various advisory and mentor roles, he Founded the Patient Information Forum, is a NW Service Champion for Diabetes UK and an Honorary Lecturer at the University of Salford. @MarkDuman; http://uk.linkedin.com/in/mduman

Dr Elin Haf Davies founded Aparito in 2014 on the back of 21 years of clinical (as Senior Clinical Research Nurse and Trial Administrator, Great Ormond Street Children’s Hospital, London), research (PhD, University College London, UK) and regulatory experience (as Scientific Assessor at both the Medicines Health Regulatory Authority (MHRA) and the European Medicine Agency (EMA)).

Claire is a Lead Principal at Oxford Science Innovation, a position she assumed in March 2021. She sits on the Board of Dark Blue Therapeutics. Prior to OSI Claire headed up Investment at BioCity where she developed the strategy, created a number of early stage ventures and supported companies on the Board in areas such as Therapeutics (Rinri TX, Fast BioPharma and BiVictriX), Synthetic Biology (NanoSyrinX) and Precision Medicine (Kinomica). Claire has previously worked in AstraZeneca supporting early drug repositioning and strategy and within the Corporate VC arm and also spent 11 years in the USA at Sanofi- Genzyme and UCB Pharma in a variety of roles covering Scientific to Project management. She holds a Ph.D. and Honours degree in Physiology, an MBA and is certified in Investment Management

Amine is a neuroradiologist and medical director practicing in medical imaging institutes in Switzerland. He is also the Chief Medical Officer of Cerebriu, a medtech company based in Copenhagen, which develops intelligent software to simplify radiology. Dr Korchi shares his time between the clinical frontline and entrepreneurial ventures in medical technologies. He is an investor and an advisor in the field of innovative technologies applied to healthcare and life sciences.

Thorben Seeger is a thought leader in science-based solutions that propel genomics and personalised medicine forward. Bringing over 14 years of experience in enterprise technology and financial solutions, Thorben has successfully developed commercial strategies and led high-performance business development teams for global powerhouses, including Goldman Sachs, Morgan Stanley, and Duel Tech.
Thorben Seeger leads Lifebit’s international commercial operations. His thought leadership and strategic innovation in the genomics field has firmly established Lifebit as the leading software technology powering precision medicine programs worldwide. With Lifebit, Thorben strategically guides and brings to life the world’s leading national precision medicine programs, including Lifebit clients Genomics England and the Danish National Genome Center. In addition, he oversees strategic partnerships with pharmaceutical giants such as Boehringer Ingelheim, where Lifebit’s AI-powered platform will track global disease outbreaks.

Aline Noizet is a connector by heart! Very active actor in the health and innovation sector with a strong international network, she is on top of the latest digital health trends and technologies. With more than 10 years working in the digital health space, Aline has been supporting more than 400 startups and corporations over the years and has acquired strong international experience working with and for startups, investors, pharmaceuticals, payers, medtech, patient associations, regulators etc

Lisa obtained her PhD in Immunology in Buenos Aires, Argentina, then traveled to London for a postdoc at the National Institutes of Medical Research (now the Crick Institute) and was later was drawn to science communication. She has written for the Economist, the New Scientist, Nature, Scientific American, the Observer and Times before joining the Nature Biotechnology team to run the news section.